Indications for: Droperidol

To reduce incidence of nausea and vomiting associated with surgical and diagnostic procedures.

Adult Dosage:

Max initial dose: 2.5mg IM or slow IV; may give additional 1.25mg doses to achieve desired effect.

Children Dosage:

<2yrs: not recommended. ≥2yrs: max initial dose: 0.1mg/kg.

Droperidol Contraindications:

QT prolongation (including congenital long QT syndrome).

Droperidol Warnings/Precautions:

Perform ECG prior to administration to determine if prolonged QT interval present; if prolonged, do not administer unless treatment outweighs risks; if treating, monitor for arrhythmias: perform ECG prior to treatment and 2–3hrs after completion. Risk factors for QT prolongation: CHF, bradycardia, cardiac hypertrophy, hypokalemia, hypomagnesemia, >65yrs, alcohol abuse. Pheochromocytoma. Hepatic or renal impairment. Elderly. Debilitated. Critically ill. Labor & delivery: not recommended. Pregnancy (Cat.C). Nursing mothers.

Droperidol Classification:


Droperidol Interactions:

Risk of QT prolongation with concomitant Class I and III antiarrhythmics, MAOIs, antimalarials, calcium channel blockers, benzodiazepines, volatile anesthetics, IV opiates, other drugs that prolong QT interval. Caution with drugs that induce hypokalemia, hypomagnesemia (eg, diuretics, laxatives). Additive effects with CNS depressants (eg, barbiturates, tranquilizers, opioids, general anesthetics). Possible hypertension with concomitant fentanyl citrate inj.

Adverse Reactions:

Hypotension, tachycardia, dysphoria, drowsiness, restlessness, hyperactivity, anxiety, QT prolonation, torsade de pointes, cardiac arrest, ventricular tachycardia, neuroleptic malignant syndrome, post-op hallucinatory episodes.


Formerly known under the brand name Inapsine.

How Supplied:

Contact supplier.